Drug-induced oral lichenoid reactions in patients consuming antihypertensive drugs

Document Type : original articles

Authors

1 Department of Oral and Maxillofacial School of Dentistry, Urmia University of Medical Sciences, Urmia, Iran

2 Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Abstract

Objectives: High blood pressure (HBP) is a persistent and widespread condition, and increasing numbers of patients are taking medication to reduce HBP symptoms and control blood pressure. Patients taking specific antihypertensive medications have been reported to experience oral lichenoid reactions. Various antihypertensive drugs have entered the market, and it is essential to study how they may affect the occurrence of oral lichenoid reactions. This study aimed at assessing the frequency of drug-induced oral lichenoid responses in patients receiving antihypertensive medications.
Methods: Four hundred fifty patients who took hypertension medications referring to Seyed al-Shohdai Hospital in Urmia in 2021 were the subject of this cross-sectional study. After the patient's first visit to the hospital, a thorough medical history was obtained from them. The type, dose, and duration of antihypertensive medications taken at the study's time were questioned and documented together with demographic data. The diagnosis of the oral lichenoid reactions was then made by examining the patients. Chi-square and Spearman's correlation tests were used in SPSS version 26 to evaluate the data.
Results: Oral lichenoid reaction was observed in about 3.3% of patients. The average age of patients who showed oral lichenoid reaction was 53.7 ± 7.1, they had taken medicine for an average of 1 to 30 months, and 66.7% were female.
Conclusions: Patients taking antihypertensive drugs, e.g., hydrochlorothiazide, methyldopa, metoprolol, and propranolol, should be examined and followed up regarding oral lichenoid reactions.

Keywords

References

1.Song P, Zhang Y, Yu J, et al. Global prevalence of hypertension in children: a systematic review and meta-analysis. JAMA Pediatr. 2019;173(12):1154-1163.
2.Atibila F, Hoor Gt, Donkoh ET, et al. Prevalence of hypertension in Ghanaian society: a systematic review, meta-analysis, and GRADE assessment. Syst Rev. 2021;10(1):220.
3.Zhang X, Zhang Z, Ye R, et al. Prevalence of hypertension and its relationship with altitude in highland areas: a systematic review and meta-analysis. Hypertens Res. 2022 ;45(8):1225-1239.
4.Jackson R, Bellamy M. Antihypertensive drugs. Curr Pharm Des. 2015;15(6):280-5.
5.Yousefi H, Abdollahi M. An update on drug-induced oral Reactions. J Pharm Pharm Sci. 2018;21(1):171-183.
6.Kamath VV, Setlur K, Yerlagudda K. Oral lichenoid lesions-a review and update. Indian J Dermatol. 2015;60(1):102.
7.Rankohi ZE, Shabanian M, Maleki D. Oral Manifestations of Patients Taking Anti-Hypertensive Medications. Iran Dent Assoc. 2020, 32(3 And 4): 83-88.
8.Thongprasom K. Is Simvastatin Associated with Oral Lichenoid Drug Reaction? J Dent Indonesia. 2018; 25(3):175-7.
9.Almeyda J, Levantine A. Drug reactions. XVI. Lichenoid drug eruptions.bbBr J Dermatol.1971;85(6): 604-7.
10.DeRossi SS, Ciarrocca KN. Lichen planus, lichenoid drug reactions, and lichenoid mucositis. Dent Clin North Am. 2005;49(1):77-89.
11.Bakhtiari S, Sehatpour M, Mortazavi H, et al. Orofacial manifestations of adverse drug reactions: a review study. Clujul Med. 2018;91(1):27-36.
12.Van der Meij E, Mast H, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol. 2007;43(8):742-8.
13.Kunadia A, Shulman K, Sami N. Spironolactone-Induced Lichenoid Drug Reaction and Subsequent Diffuse Eruptive Squamous Cell Carcinomas Successfully Treated With Systemic Methotrexate. Cureus. 2021;13(9):e17713.
14.Asano A, Nakai K, Tsuruta D. Lichenoid drug eruption associated with bisoprolol transdermal patches. Contact Dermatitis. 2022;86(2):139-141.
15.Cutler T. Lichen planus caused by pyrimethamine. Clin Exp Dermatol. 1980;5(2):253-6.
16.Zain RB. Oral lichenoidbbreactions during antimalarial prophylaxis with sulphadoxine-pyrimethamine combination. Southeast Asian J Trop Med Public Health. 1989;20(2):253-6.
17.Lakshmi C, Srinivas C, Ramachandran B, et al. Perforating lichenoid reaction to amlodipine. Indian J Dermatol. 2008;53(2):98-9.
18.Upadhayai JB, Nangia AK, Mukhija RD, et al . Cutaneous reactions due to antihypertensive drugs. Indian J Derm. 2006;51(3):189.
19.Manuel R, George R, Martin AM, et al. Grinspan's Syndrome. BMH Med J ISSN 2348–392X. 2019;7(1):20-2.
20.Salam A, Huffman MD, Kanukula R, et al. Two‐drug fixed‐dose combinations of blood pressure‐lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. J Clin Hypertens (Greenwich). 2020;22(10): 1769-1779.
21.Sabbah DA, Hajjo R, Sweidan K, et al. An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors. Curr Comput Aided Drug Des. 2021;17(6):817-830.
22.Hogan J, Radhakrishnan J. The assessment and importance of hypertension in the dental setting. Dent Clin North Am. 2012;56(4):731-45.
23.Popescu SM, Scrieciu M, Mercuţ V, et al. Hypertensive patients and their management in dentistry. ISRN Hypertension. 2013;2013.
24.Teoh L, Moses G, McCullough MJ. A review and guide to drug‐associated oral adverse effects-Dental, salivary and neurosensory reactions. Part 1. J Oral Pathol Med. 2019;48(7):626-636.
25.Cetinkaya BO, Sumer M, Tutkun F, et al. Influence of different suturing techniques on periodontal health of the adjacent second molars after extraction of impacted mandibular third molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(2):156-61.
26.Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg. 2008;46(1):15-21.
27.McCartan B, McCreary C. Oral lichenoid drug eruptions. Oral Dis. 1997;3(2):58-63.
28.Elliott WJ. Systemic hypertension. Curr Probl Cardiol. 2007;32(4):201-59.
29.Ferdinand KC, Nasser SA. Management of Essential Hypertension. Cardiol Clin. 2017;35(2):231-246.
30.Wu Y, Cao Y, Song J, et al. Antihypertensive drugs use over a 5-year period among children and adolescents in Beijing, China: An observational study. Medicine (Baltimore). 2019;98(40) :e17411.
31.Kumar P, Mastan K, Chowdhary R, et al. Oral manifestations in hypertensive patients: A clinical study. J Oral Maxillofac Pathol. 2012;16(2):215-21.
32.Borhanmojabi K, Rezaei F, Esfehani M. Prevalence of oral lichenoid reactions in a sample of Qazvin population (2004). JQUMS. 2011;15(3):91-94.
33.Click M. Burket's oral medicine. Chapter 3: PMPH, USA; 2015.
34.Neville BW, Damm DD, Allen C, et al. Oral and maxillofacial pathology. Elsevier Health Sciences; 2015.
35.Kaomongkolgit R. Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. J Drugs Dermatol. 2010;9(1):73-5.
36.Seyedmajidi M, Motallebnejad M, Foroughi R, et al.Clinical and histopathological findings in 26 patients with oral lichenoid lesions. JbbBabol Uni Med Sci. 2010;12(3):72-78.
37.Dunsche A, Kästel I, Terheyden H, et al. Oral lichenoid reactions associated with amalgam: improvement after amalgam removal. Br J Dermatol. 2003;148(1):70-6.
38.Yuan A, Woo S-B. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(1):35-47.
39.Jayakaran TG. The effect of drugs in the oral cavity-A review. J Pharm Scibb& Res. 2014;6(2):89.
40.Fortuna G, Aria M, Schiavo JH. Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol. 2017;73(12):1523-1537.
Cardiovascular Biomedicine
Volume 2, Issue 2
December 2022
Pages 3-10

Files

History

  • Receive Date: 26 November 2022
  • Revise Date: 16 February 2023
  • Accept Date: 04 March 2023
  • First Publish Date: 04 March 2023

Share

How to cite

Statistics